Lourens Bloem

Utrecht University

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Judith Gulikers

UCSF Cardiovascular Research Institute

NETHERLANDS

View details

Anna Maria Gerdina Pasmooij

Utrecht University

NETHERLANDS

View details

Rick Vreman

Utrecht University

NETHERLANDS

View details

Toine Egberts

Utrecht University

NETHERLANDS

View details

Paula van Hennik

Group Head Clinical Affairs

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lourens Bloem

Research Interests

Explore related searches

Contact this professor

Articles (15)

Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union

Leftover of Amoxicillin Suspension After Use by Children in the Netherlands

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations

A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization Process

High cost oncology drugs without proof of added benefit are burdening health systems

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study

Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results

European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006–2020

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs

Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing

Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis.

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs

Collaborators (5)

Judith Gulikers

Anna Maria Gerdina Pasmooij

Rick Vreman

Toine Egberts

Paula van Hennik

Make your next move.